← Sticker Wall MODEL · DETAIL

Traditional Chinese Medicine AI-Assisted Diagnosis and Treatment & Digital Licensing of Classical Formulas

1) SaaS subscription: Charging an AI-assisted diagnostic system usage fee billed per consultation or annually; 2) Databa

MODEL

Key Fields

FIELD STAMPS

IndustryHealthcare / Elderly Care

RegionChina

ScaleMid-size

ChannelOnline

📌 Background

Anticipation for the first 'Traditional Chinese Medicine AI stock' is rising. Gushentang is driven by a dual-engine of technology and globalization, while Maijing has initiated the construction of the Huang Huang Classical Formula Evidence-Based Big Data Library. According to project disclosures, the library plans nine standardized core libraries containing 300,000 real-world medical cases. It can increase primary care physicians' diagnosis and treatment efficiency by 30% to 40% and reduce ineffective prescriptions by 70%. Classical formulas and senior TCM practitioners' experiences are being transformed into licensable digital assets.

👤 Target Customers

Chain TCM clinics, small and medium-sized clinics, internet medical platforms, and traditional Chinese medicine enterprises, with private medical clinics, pharmaceutical companies, and large language model vendors as the primary payers.

💰 Revenue Streams

1) SaaS subscription: Charging an AI-assisted diagnostic system usage fee billed per consultation or annually; 2) Database licensing: Charging pharmaceutical companies and research institutions for classical formula knowledge graphs and evidence-based database licenses based on the scope of authorization; 3) API revenue sharing: Earning a share of revenue based on API call volumes from large model vendors; 4) Clinic delivery: Providing system deployment and data annotation for chain TCM clinics as an opportunistic item, with no public disclosure on the specific revenue amount.

🧮 Cost Structure

Costs related to the collection and structured annotation of senior TCM practitioners' experiences, evidence-based databases and AI R&D, regulatory and ethical reviews, and sales and delivery teams.

🛡️ Moat

Exclusive classical formula evidence-based database and real-world diagnosis and treatment data flywheel, dual barriers of renowned practitioner IP and efficacy data, along with medical AI access qualifications.

🔑 Keys to Success

Secure exclusive rights to the digitization of senior TCM practitioners' experience
Co-build a data ecosystem with leading chain clinics and large language model vendors
Advance certification and compliance ahead of time in alignment with medical AI regulatory requirements

⚠️ Risks

Long approval cycles and uncertain outcomes for Class III medical AI certificates
Shrinkage of core asset value after the expiration of renowned practitioner IP licenses
Rapid iteration of general capabilities in large language models impacting the pricing power of vertical products

🏢 Cases

Maijing and Huang Huang Classical Formula Evidence-Based Big Data Library
Gushentang TCM AI Going Global and Diagnostic Digitization
Transsion Suwen and Hongyitang Imperial Medical Pulse Agent

📊 SWOT Analysis

Strengths

High scarcity of evidence-based databases for classical formulas by renowned practitioners such as Huang Huang
Real-world diagnosis and treatment data closed-loop brought by chain scenarios like Gushentang
TCM AI going global opens up incremental markets in Southeast Asia, Europe, and the Americas

Weaknesses

Significant controversy over TCM standardization, with unclear liability subjects for AI diagnosis
Cross-institution prescription data sharing restricted by privacy regulations

Opportunities

Vast number of primary care TCM clinics with a clear, rigid demand for AI-assisted diagnosis and treatment
Approval of classical formula preparations requires evidence-based data, increasing licensing demand

Threats

Rapid evolution of general large language models squeezing the space for vertical TCM SaaS
Intensified competition for exclusive resources of renowned practitioners, increasing licensing costs

Sources